The latest announcement is out from InhaleRx Limited ( (AU:IRX) ).
InhaleRx Limited reported a reduction in its annual loss by 16.2% for the year ending December 31, 2024, amounting to $1,209,373. Despite the improvement, the company did not declare any dividends, and its net tangible assets per ordinary security decreased significantly from 0.35 cents to -0.03 cents, indicating ongoing financial challenges.
More about InhaleRx Limited
InhaleRx Limited operates in the healthcare industry, focusing on the development and provision of inhalation-based therapies. The company is committed to advancing medical treatments through innovative delivery systems, primarily targeting respiratory conditions.
YTD Price Performance: -32.50%
Average Trading Volume: 154,894
Technical Sentiment Signal: Buy
Current Market Cap: A$5.76M
Find detailed analytics on IRX stock on TipRanks’ Stock Analysis page.